254 cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
F. Journe, M. Wiedig, R. Morandini, F. Sales, G. Ghanem, A. AwadaVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)71960-1
File:
PDF, 59 KB
english, 2010